logo-loader

Citi upgrades Smith & Nephew to 'buy' from 'sell'

Published: 10:23 10 Sep 2012 EDT

no_picture_pai

Smith & Nephew (LON:SN.) has been upgraded to 'buy' from 'sell' by analysts at Citi, who expect a share buyback to begin next year.

Citi says it forecasts the medical device group to have a net cash position of around $500 million for the end of 2012. 

"The company has stated that it is looking for acquisition targets but will return capital if it fails to find any. 

"We believe that SN can do both, our calculations suggest that the company could buy back around$1.7bn of shares over the next four years and still raise $2.5bn of debt whilst maintaining an investment grade rating," it said it a note.

Citi has a new target price of 790 pence for the stock (current price: 679 pence).

Xeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for...

Xeris Biopharma CEO Paul Edick joined Steve Darling from Proactive to share news the company had a successful 2023, with a final tally of 164 million USD, which is at the upper end of their forecast. The company concluded the year with 72 million USD in cash, surpassing their initial projections...

9 hours, 53 minutes ago